Posted by Michael Wonder on 20 Oct 2024
Avadel Pharmaceuticals announces FDA approval of Lumryz (sodium oxybate) extended release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy
17 October 2024 - Granted orphan drug exclusivity in paediatric narcolepsy patients 7 years and older through 16 October 2031.
Avadel Pharmaceuticals announced today that the US FDA has approved its supplemental new drug application for Lumryz for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
